MRNA241213P35500
- 0.11
- 0.000.00%
Moderna Newsroom
Moderna Options Spot-On: On December 12th, 121.57K Contracts Were Traded, With 723.43K Open Interest
On December 12th ET, $Moderna(MRNA.US)$ had active options trading, with a total trading volume of 121.57K options for the day, of which put options accounted for 87.04% of the total transactions,
Carisma Downgraded by Baird Over Lack of Near-term Catalysts
MicroStrategy Shares Could Surge Even Higher If Added to Nasdaq 100 on Friday, Crypto Analyst Says
Super Micro Computer Teeters On Edge Of Nasdaq 100: Can XAI, Nvidia Help Stabilize Trajectory?
MicroStrategy Stock Could Get Added to the Nasdaq 100 Because of a Quirk
Unusual Options Activity: ACI, FTI and Others Attract Market Bets, ACI V/OI Ratio Reaches 75.0
EST Dec 11th Morning Delivery - In the last two hours of trading, 9 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Moderna Reinstated With an Underperform at BofA
BofA Securities Initiates Moderna(MRNA.US) With Sell Rating, Announces Target Price $41
BofA Downgrades Moderna, Says It's 'Tough Time' to Be Vaccine Maker
BofA Restarts Coverage of 11 Large-cap Biopharmas
FDA Highlights Safety Challenges And Development Needs For Pediatric RSV Vaccines Amid Historical Concerns And Recent MRNA Trial Pauses; Focus On Addressing Unmet Needs For Infants And Toddlers.
Unpacking the Latest Options Trading Trends in Moderna
Expert Outlook: Moderna Through The Eyes Of 19 Analysts
B of A Securities Reinstates Underperform on Moderna, Announces $41 Price Target
Moderna Analyst Ratings
Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
S&P 500 Gains in 2024, but Not All Stocks Are Celebrating: See the 10 Worst Performers Here
Here's Why We're Watching Moderna's (NASDAQ:MRNA) Cash Burn Situation
Piper Sandler Maintains Moderna(MRNA.US) With Buy Rating, Maintains Target Price $69